卡瑞利珠单抗联合FOLFOX4治疗与FOLFOX4单独治疗中晚期原发性肝癌的效果及安全性对比

Comparison of Efficacy and Safety of Camrelizumab Combined with FOLFOX4 and FOLFOX4 Alone in the Treatment of Advanced Primary Hepatoma

目的通过对比卡瑞利珠单抗联合FOLFOX4方案与单纯FOLFOX4方案在治疗中晚期原发性肝癌患者中的临床疗效和不良反应,为免疫治疗在中晚期原发性肝癌的治疗提供依据。方法选取中晚期原发性肝癌患者100例,根据治疗方案分为2组,实验组50例采用卡瑞利珠单抗联合FOLFOX4化疗和对照组50例采用单纯FOLFOX4化疗。治疗4周期后评估疗效,并观察不良反应和患者生存质量。结果实验组疾病控制率为92.00%,对照组疾病控制率为76.00%,实验组疾病控制率显著高于对照组(P<0.05)。治疗后,实验组患者AFP、CEA、CA199、总胆红素、直接胆红素、间接胆红素、胆碱酯酶、ALT、AST、ALP、LDH均显著优于对照组(P<0.05)。治疗后2组患者总不良反应发生率比较,差异不具有统计学意义(P>0.05)。2组患者生存质量比较,实验组KPS评分、PS评分和QOL评分均高于对照组(P<0.05)。结论卡瑞利珠单抗联合FOLFOX4化疗治疗中晚期原发性肝癌的临床疗效优于单纯化疗,且不增加不良反应。

Objective To compare the clinical efficacy and adverse reactions of camrelizumab combined with FOLFOX4 and FOLFOX4 alone in the treatment of patients with advanced primary hepatoma,and to provide a basis for immunotherapy in the treatment of advanced primary hepatoma.Methods A total of 100 patients with advanced primary hepatoma were selected and divided into 2 groups according to the grouping criteria,with 50 cases in each group.The experimental group was treated with camrelizumab combined with FOLFOX4 and the control group was treated with FOLFOX4 alone.The efficacy was evaluated after 4 cycles,and the adverse reactions and quality of life were observed.Results The experimental group had disease control rate as 92.00%,which was 76.00%in the control group.The experimental group had obviously higher disease control rate than the control group(P<0.05).After treatment,AFP、CEA、CA199、total bilirubin、direct bilirubin、indirect bilirubin,、cholinesterase、ALT、AST、ALP and LDH in the experimental group were significantly better than those in the control group(P<0.05).There was no significant difference in the incidence of total adverse reactions between 2 groups after treatment(P>0.05).The KPS score,PS score and QOL score of the experimental group were higher than those of the control group(P<0.05).Conclusion The clinical efficacy of camrelizumab combined with FOLFOX4 in the treatment of advanced primary hepatoma is better than that of chemotherapy alone and does not increase the side effects of FOLFOX4.